Predicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach.

AIM: To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection.

MATERIALS AND METHODS: The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow.

RESULTS: All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors.

The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model.

CONCLUSIONS: The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.

关键词

作者简介

Anna Tsygankova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: anna.tsygankova.inf@gmail.com
ORCID iD: 0000-0003-3766-1868
SPIN 代码: 6583-0476
Researcher ID: HDM-3718-2022

MD

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Vladimir Chulanov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: vladimir.chulanov@rcvh.ru
ORCID iD: 0000-0001-6303-9293
SPIN 代码: 2336-4545

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Andrey Gerasimov

Central Research Institute of Epidemiology

Email: andr-gerasim@yandex.ru
ORCID iD: 0000-0003-4549-7172
SPIN 代码: 4742-1459
Scopus 作者 ID: 141741

Dr. Sci. (Phys.-Math.), Associate Professor

俄罗斯联邦, Moscow

Elena Volchkova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: antononina@rambler.ru
ORCID iD: 0000-0003-4581-4510
SPIN 代码: 3342-4681

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Anton Privalenko

Central Research Institute of Epidemiology

Email: antochka001@mail.ru
ORCID iD: 0009-0001-4827-1673

medical statistician

俄罗斯联邦, Moscow

Viktoriya Bakhtina

Specialized Clinical Infectious Hospital

Email: dom-167@mail.ru
ORCID iD: 0000-0001-6065-2922
SPIN 代码: 9446-5319

MD, Cand. Sci. (Med.)

俄罗斯联邦, Krasnodar

Vladimir Khabudaev

Irkutsk Regional Clinical Hospital

Email: ioikb@ioikb.ru

MD, Cand. Sci. (Med.)

俄罗斯联邦, Irkutsk

Dina Baimukhambetova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: dbaimukhambietova@bk.ru
ORCID iD: 0000-0002-5518-9301
SPIN 代码: 9039-7431

6th year student

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

参考

  1. Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acuteillness severity in the NHS. London: RCP; 2012.
  2. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi: 10.1016/j.jinf.2020.04.021
  3. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020;9(2):428–436. doi: 10.21037/apm.2020.03.26
  4. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versii 3–18. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. [Internet]. (In Russ). Available at: https://minzdrav.gov.ru/ministry/med_covid19.
  5. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328
  6. Prikaz Ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 9 noyabrya 2012 g. № 758n “Ob utverzhdenii standarta spetsializirovannoi meditsinskoi pomoshchi pri bolezni, vyzvannoi virusom immunodefitsita cheloveka (VICh-infektsii)” [Internet]. (In Russ). Available at: https://minzdrav.gov.ru/documents/8837-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-9-noyabrya-2012-g-758n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-bolezni-vyzvannoy-virusom-immunodefitsita-cheloveka-vich-infektsii.
  7. Gerasimov AN, Morozova NI. Parametric and Nonparametric Methods in Medical Statistics. Epidemiology and Vaccinal Prevention. 2015;14(5):6–12. (In Russ). doi: 10.31631/2073-3046-2015-14-5-6-12
  8. Chen R, Liang W, Jiang M, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. 2020;158(1):97–105. doi: 10.1016/j.chest.2020.04.010
  9. Nagibina MV, Smirnov NA, Bessarab TP, et al. Analysis of the course and outcomes of COVID-19 in HIV infected patients according to the infectious diseases’ hospital of Moscow. Clinical Medicine (Russian Journal). 2023;101(2-3):93–100. (In Russ). doi: 10.30629/0023-2149-2023-101-2-3-93-100
  10. Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021;73(7):e1964–e1972. doi: 10.1093/cid/ciaa1339
  11. Yendewa GA, Perez JA, Schlick K, Tribout H, McComsey GA. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX). Open Forum Infect Dis. 2021;8(7):ofab272. doi: 10.1093/ofid/ofab272
  12. Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022;19(1):3. doi: 10.1186/s12981-021-00427-y
  13. Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin Infect Dis. 2021;73(7): e2095–e2106. doi: 10.1093/cid/ciaa1605
  14. Kassanjee R, Davies MA, Ngwenya O, et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa. J Int AIDS Soc. 2023;26(6):e26104. doi: 10.1002/jia2.26104
  15. Sun J, Jiang R, Shao Y, et al. Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19. Chin Med J (Engl). 2023;136(22):2753–2755. doi: 10.1097/CM9.0000000000002902
  16. Marmorino F, Salvatore L, Barbara C, et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer. 2017;116(3):318–323. doi: 10.1038/bjc.2016.413
  17. Lu J, Wei Z, Jiang H, et al. Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study. J Surg Res. 2018;228:314–321. doi: 10.1016/j.jss.2018.03.035
  18. Gulhar R, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: http://www.ncbi.nlm.nih.gov/books/NBK519570.
  19. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5): 377–382. doi: 10.1136/thorax.58.5.377

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Study design.

下载 (737KB)
3. Fig. 2. The prognostic value to mortality correlation according to the derived prognostic model for advanced HIV patients co-infected with COVID-19.

下载 (550KB)

版权所有 © Eco-vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##